Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 6,301 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Donald Notman sold 6,301 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the sale, the insider now directly owns 204,563 shares of the company's stock, valued at $1,603,773.92. This represents a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.81, for a total value of $86,839.39.

Ocular Therapeutix Trading Down 0.9 %

Shares of NASDAQ:OCUL traded down $0.07 on Friday, reaching $7.57. 770,143 shares of the company traded hands, compared to its average volume of 906,225. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The business's 50-day simple moving average is $8.48 and its 200 day simple moving average is $9.00. The stock has a market capitalization of $1.19 billion, a P/E ratio of -5.73 and a beta of 1.22. Ocular Therapeutix, Inc. has a 52 week low of $4.06 and a 52 week high of $11.77.

Institutional Trading of Ocular Therapeutix

A number of institutional investors have recently modified their holdings of OCUL. AlphaQuest LLC purchased a new stake in Ocular Therapeutix in the fourth quarter worth about $53,000. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix in the fourth quarter worth about $1,722,000. Aigen Investment Management LP purchased a new stake in Ocular Therapeutix in the fourth quarter worth about $159,000. Victory Capital Management Inc. lifted its holdings in Ocular Therapeutix by 300.4% in the fourth quarter. Victory Capital Management Inc. now owns 68,871 shares of the biopharmaceutical company's stock worth $588,000 after buying an additional 51,671 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Ocular Therapeutix by 1.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock worth $9,663,000 after buying an additional 21,025 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OCUL has been the topic of a number of research analyst reports. Scotiabank initiated coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and an average target price of $16.71.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.